Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB11 versus Lucentis in neovascular age-related macular degeneration
2017-000422-36Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- May 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing SB11 with Lucentis (2 arms). Started May 2017; status: completed.
02
Drugs
ranizurelranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2017-000422-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000422-36.